IMUX SEC Filings: 8-K, 10-Q, S-3 & 424B – Immunic

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Apr 22, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Immunic, Inc. Hosts Progressive Multiple Sclerosis R&D Day Webinar

Nov 5, 2026

8-K

Immunic, Inc. Announces Resignation of Board Director Dr. Duane Nash

Sep 11, 2026

8-K

Immunic, Inc. Hosting Relapsing Multiple Sclerosis Research and Development Day Webinar

Sep 9, 2026

8-K

Immunic Appoints Elena Ridloff to Board of Directors

Aug 11, 2026

8-K

Immunic, Inc. Releases Updated Corporate Presentation

Jul 14, 2026

8-K

Immunic, Inc. Announces Board of Directors Changes

Jul 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

May 30, 2025

424B5

SHELF OFFERING | Bank: Leerink Partners

May 28, 2025

424B5

REGISTERED OFFERING

Apr 9, 2025

424B5

ATM | Offering amount: $80,000,000

Jun 10, 2024

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 55,944,850

Apr 30, 2024

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 13,693,104 | Warrants amount: 5,096,552

Dec 20, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 1, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 12, 2026

S-3/A

SHARE RESALE REGISTRATION

Apr 30, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Apr 9, 2026

S-3

SHARE RESALE REGISTRATION

Apr 2, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Mar 4, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 2, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Feb 20, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

Aberdeen Group plc (Filed by)

Nov 2, 2026

Nagel Robert Thorvald (Reporting)

Sep 18, 2026

BIOTECHNOLOGY VALUE FUND L P (Reporting)

Sep 18, 2026

SCHEDULE 13G

ORBIMED ADVISORS LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Nantahala Capital Management, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Commodore Capital LP (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 5, 2026

CORRESP

Form CORRESP - Correspondence

May 1, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 6, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 3, 2024

CORRESP

Form CORRESP - Correspondence

May 29, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 1, 2024

Immunic, Inc. IMUX · SEC Filings